抑制PR刺激G6PD表达,以增强光线乳腺癌中的恶性瘤
Jae Woong Jeong1,2, Janghee Lee3, Soong June Bae4,5
1Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea.
Cell death & disease
|December 21, 2025
概括
较低的孕激素受体 (PR) 表达在光线乳腺癌中,通过增加通过酸 (PPP) 途径的葡萄糖代谢,促进了攻击性. 准葡萄糖-6-酸盐脱酶 (G6PD) 显示出治疗的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 发光性乳腺癌是最常见的亚型.
- 较低的孕激素受体 (PR) 表达与生存率低下有关,但其在癌症攻击性中的作用尚不清楚.
- 之前的研究表明PR和[18F]氧葡萄糖正子发射断层扫描 (FDG-PET) 标准化吸收值 (SUV) 之间的反相关性.
研究的目的:
- 研究PR表达和葡萄糖代谢之间的联系,特别是酸通路 (PPP),在光线乳腺癌中.
- 为了确定PR是否影响癌细胞的增殖和攻击性.
- 探索G6PD抑制作为一种治疗策略.
主要方法:
- 一个单细胞RNA测序 (scRNA-seq) 分析已发表的数据集.
- 在MCF7和T47D发光性乳腺癌细胞系中进行PR沉默.
- 对细胞增殖,PPP活性和葡萄糖-6-酸盐脱酶 (G6PD) 表达的评估.
- 用G6PD抑制剂 (G6PDi) 治疗PR沉默细胞.
主要成果:
- scRNA-seq揭示了PR表达低的上皮细胞表现出增加的增殖和PPP活性,以及更高的G6PD表达.
- 细胞系中的PR沉默加速了细胞的增殖,增加了PPP活性和G6PD表达.
- 抑制G6PD降低了PR抑制的乳腺癌细胞的攻击性.
结论:
- 通过PPP增加葡萄糖利用率,PR Knockdown可以增强乳腺癌的攻击性.
- 准G6PD是针对侵袭性光线乳腺癌的潜在治疗策略.
- 低PR表达可以作为生物标志物来识别可能受益于G6PD向治疗的患者.
相关概念视频
02:23Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
01:31The Intrinsic Apoptotic Pathway
8.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.2K
01:23Negative Regulator Molecules
38.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.2K
02:38The Ras Gene
7.0K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.0K